Remove 2026 Remove Competition Remove Networking
article thumbnail

Sandoz to build biologics plant in Slovenia

European Pharmaceutical Review

“Not only does the location has offer competitive costs [but it has] proximity to our existing European-based production and commercial operations.” Full operations is provisionally planned for late 2026. This brings the total new investment commitment to the network in the past few years to €250 million.

article thumbnail

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

PM360

Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. Starting in 2026, the provision will affect 10 Part D drugs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Beyond transparent pricing: decoding the strategies of major PBMs

Clarivate

These moves mark a strategic shift towards greater transparency and predictability, driven by regulatory pressures and rising competition from market disruptors. The model is confined to ESI’s own retail pharmacy network; it avoids MAC reimbursement limits, raising potential cost concerns for plan sponsors.

Retail 59
article thumbnail

What a string of semaglutide biosimilars could mean for Mainland China

Clarivate

Competition is expected to intensify in the next few years as both Novo Nordisk and Eli Lilly plan to launch their respective weight-loss drugs in Mainland China. Robust clinical data around multiple cardiometabolic indicators supported by all three assets is poised to lead widespread adoption in Mainland China.

article thumbnail

U.S. market access landscape: A push for control is erasing the boundary between payers and providers in U.S. healthcare

Clarivate

Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026. Lines are blurring between payers and providers More and more, large integrated delivery networks and national payers are battling each other for greater control over patient costs and outcomes.

article thumbnail

How retailers and “payviders” are disrupting U.S. healthcare in 2024

Clarivate

Humana is following a similar growth strategy as it sharpens competition with UnitedHealthcare in the Medicare Advantage sector. Signify’s healthcare platform also assists 65,000 provider partners to participate in value-based care with nearly 1 million attributed lives Oak Street Health acquisition May 2023 CVS acquired Oak Street for $10.6

Retail 52
article thumbnail

Medicare Advantage Policy and Regulation Updates: What Payers Need to Know in 2024 and Beyond

Clarify Health

That way, they can continue to grow membership and thrive against the competition. In 2026, payers will need to send prior authorization decisions within 72 hours for urgent requests and seven business days for standard requests. These changes are designed to make care easier to access for enrollees.